Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 29, 2010 Brian Orelli	How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years.
The Motley Fool March 3, 2010 Brian Orelli	A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool March 30, 2009 Brian Orelli	Change the Game? Change the Rules! There are ways for investors to get around Obama's plan to lower health care costs. Investing in drug companies in this time of "change" doesn't have to be scary. You've just got to find rule breaker-type drugmakers, because playing by the rules isn't going to cut it anymore.
The Motley Fool August 4, 2010 Brian Orelli	No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's.
The Motley Fool July 29, 2009 Brian Orelli	Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them.
The Motley Fool May 19, 2010 Brian Orelli	The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd.
The Motley Fool August 11, 2010 Brian Orelli	Dang! This Drug Is Shining Brighter Vertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool April 11, 2011 Brian Orelli	Clinical Trial Fail? Forget About It. A failure of Medivation and Pfizer's dimebon was expected.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
The Motley Fool November 9, 2010 Brian Orelli	Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals.
The Motley Fool June 30, 2009 Brian Orelli	A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention.
The Motley Fool December 29, 2009 Brian Orelli	Some Brand-Name Patents: Going, Going, Gone in 2010 Generic drug competition is coming for Lipitor, Plavix, and others.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
The Motley Fool January 30, 2009 Brian Orelli	Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients.
The Motley Fool September 5, 2008 Brian Lawler	Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon.
The Motley Fool February 15, 2006 Rich Duprey	Eisai Eyes Alzheimer's Market Japan's Eisai Pharmaceuticals launches another challenge to Forest Labs' Alzheimer's drug. Investors, take note.
The Motley Fool May 30, 2006 Rich Duprey	NICE Not Playing Nice With Alzheimer's The British health authority proposes limiting availability of Alzheimer's treatments because of cost. What will this mean to drug-makers and their shareholders?
The Motley Fool August 4, 2008 Brian Lawler	Vertex on the Verge of Victory Like the majority of biotech drugmakers, Vertex's financials proved less crucial in the second quarter than the clinical trial results from the drugmaker's pipeline.
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.
The Motley Fool August 13, 2007 Rich Duprey	U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept.
The Motley Fool January 17, 2012 Brian Orelli	You Can Forget About Seeing This Drug Work Medivation and Pfizer's Dimebon fails again.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool August 26, 2010 Brian Orelli	Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers.
The Motley Fool August 29, 2008 Brian Orelli	A Lawsuit Loss to Remember Barr Pharmaceuticals and Mylan get the patent overturned on Johnson & Johnson's Alzheimer's drug.
The Motley Fool July 25, 2007 Brian Lawler	Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report.
The Motley Fool January 24, 2008 Brian Lawler	Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note.
The Motley Fool April 1, 2008 Brian Lawler	Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier.
The Motley Fool October 18, 2006 Rich Duprey	FDA Expands Alzheimer's Treatment Japan's fourth-largest pharmaceutical Eisai's Aricept wins the right to treat all stages of Alzheimer's. Investors, take note.
The Motley Fool March 17, 2008 Brian Orelli	Drugmakers That Make Rivals Green with Envy A look at some drugmakers with cash to spend: Pfizer...Wyeth... Novartis... Amylin Pharmaceuticals... Elan...Vertex Pharmaceuticals... Exelixis...
The Motley Fool April 17, 2007 Rich Duprey	Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors?
The Motley Fool June 7, 2011 Brian Orelli	Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal.
The Motley Fool January 21, 2011 Brian Orelli	Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir.
The Motley Fool November 2, 2006 Rich Duprey	Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note.
The Motley Fool May 17, 2011 Luke Timmerman	Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex.
The Motley Fool October 31, 2011 Brian Orelli	Gunning for the Leaders Hepatitis C drugs take center stage.
The Motley Fool April 21, 2011 Brian Orelli	Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan.
The Motley Fool December 14, 2006 Brian Lawler	Vertex: Coming Together Nicely If telaprevir continues to show anything like the 80%-90% rate of undetectable hepatitis C virus at end of its trials, Vertex shareholders won't be dealing with too many more down days.
The Motley Fool August 31, 2009 Brian Orelli	Don't Let Dummy Pills Make You a Dummy Investor Instead of being scared that the sugar pill will perform better than expected, pharma investors should factor it in and require more information before investing in companies with drugs that may be affected by it..
The Motley Fool January 19, 2012 Brian Orelli	New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go.
The Motley Fool June 29, 2007 Rich Duprey	No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment.
The Motley Fool June 23, 2010 Brian Orelli	Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise.
The Motley Fool January 13, 2010 Brian Orelli	JPMorgan Challenge: On the Cusp of Greatness Development-stage drugmaker Medivation has a partner and is ready for phase 3 data to roll in.
The Motley Fool February 26, 2010 Brian Orelli	A Risky Deal, but at Least It's Cheap Glaxo licenses a preclinical compound from Regulus.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool September 26, 2008 Brian Lawler	Less Is More for Vertex The company's potential hepatitis C compound proves effective with fewer dosages.